The ARAF Knockout HEK293T Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of human embryonic kidney epithelial cells engineered to disrupt the ARAF gene. This knockout model serves as a critical tool for dissecting ARAF-specific functions within the RAS-MAPK signaling axis, circumventing compensatory mechanisms often observed in single-isoform knockdowns.
HEK293T cells are widely utilized for their robust protein expression and ease of transfection, attributed to the constitutive expression of SV40 large T antigen. Their epithelial origin and human background render them relevant for studying signaling processes, while their scalability supports high-throughput screening and functional genomics studies.
ARAF encodes a serine/threonine kinase that acts as a downstream effector of RAS GTPases, including HRAS, KRAS, and NRAS. Upon activation by receptor tyrosine kinases (e.g., EGFR, PDGFR) or SRC family kinases, ARAF phosphorylates MEK1 (MAP2K1) and MEK2 (MAP2K2), which in turn activate ERK1 (MAPK3) and ERK2 (MAPK1). This cascade regulates transcription factors such as ELK1, c-FOS, and c-JUN, thereby controlling gene expression programs linked to proliferation and differentiation. ARAF also interacts with scaffold proteins like KSR1, regulatory partners including 14-3-3 proteins and HSP90/CDC37, as well as the inhibitory protein RKIP (PEBP1). Within the RAF family, ARAF exhibits distinct substrate specificity and regulatory properties compared to BRAF and CRAF, underscoring the importance of isoform-selective studies.
Deletion of ARAF in the HEK293T background, which retains endogenous RAS and other RAF isoforms, enables precise interrogation of ARAF-specific contributions to MAPK signaling. The polyclonal knockout population avoids artifacts associated with single-cell cloning and more closely mimics the heterogeneous cellular responses observed in tissue. Given the oncogenic roles of ARAF mutations in diseases such as pediatric low-grade glioma, pilocytic astrocytoma, lung adenocarcinoma, and melanoma, this model is particularly suited for studying kinase-dependent and kinase-independent functions of ARAF in tumorigenesis and drug resistance.
Researchers can employ these ARAF knockout cells to dissect RAS-MAPK pathway dynamics, assess the efficacy and specificity of RAF inhibitors, and investigate mechanisms of resistance in models of lung adenocarcinoma and melanoma. Commonly used downstream assays include Western blotting to evaluate MEK and ERK phosphorylation, RT-qPCR for transcriptional changes, phospho-ERK immunofluorescence for spatial signaling analysis, and cell proliferation or colony formation assays to assess growth phenotypes. Additionally, drug sensitivity profiling with RAF inhibitors and apoptosis assays further extend the utility of this model for preclinical oncology research. For additional technical information, please contact Ascent Research.
